Buyers are starting to ignore the Malibu
General Motors is feeling pretty good about Chevrolet these days, and not without reason. Not everything's rosy, however.
The brand's sales are up more than 6 percent this year. It has a strong line of crossovers and traditional SUVs. The new Silverado pickup promises better fuel economy and capability.
Enthusiasts are revved about the company's performance line, which includes the 2014 Corvette, Camaro Z28 and SS sport sedan. The Cruze compact, Sonic subcompact and Spark minicar comprise by far the strongest small-car lineup GM's biggest brand has ever offered.
Despite that good news, there's a new problem in an old familiar sore spot: midsize cars.
The Malibu, the midsize sedan that was a beacon of hope in GM's darkest days, has gone adrift like a Carnival cruise ship.
The last-generation Malibu, which debuted as a 2008 model, was a triumph. It put Chevy back on a lot of shopping lists with its value, looks, fuel economy and comfort. It beat the Toyota Camry and Honda Accord to win North American Car of the Year. The Malibu provided evidence that GM could build great, affordable family cars.
But the 2013 Malibu, which went on sale a year ago, has fallen flat. It's a nonfactor in arguably the most competitive passenger car segment. The Ford Fusion and Nissan Altima eclipsed the Malibu with surprising style and fuel economy, respectively. The new Accord restored Honda's status as a leader.
Malibu sales are 12 percent below last year's levels, despite what Edmunds.com says are the highest incentives on any midsize sedan. Overall U.S. vehicle sales are up nearly 7 percent. The Fusion is 25 percent ahead of last year's pace, the Accord, 26 percent.
The Altima is down 3.2 percent, proving that Chevrolet isn't the only one with problems.
The Malibu takes longer to sell than its competitors. Malibus averaged 107 days on the dealership lot in March, Edmunds said. The next-slowest turning midsize sedan is the Volkswagen Passat, at 57 days. VW just dropped a shift at the Chattanooga, Tenn., plant that builds the Passat.
“Chevrolet spent a lot of money advertising the 2008 Malibu,” said Edmunds senior analyst Michelle Krebs. “They called it ‘the car you can't ignore.' They didn't advertise the new Malibu, and people are ignoring it.”
I'm surprised by the Malibu's struggles. I've tested every version of the car, and I think it's at least as good overall as the Fusion, Accord and Camry, and more than a match for midsize sedans like the Hyundai Sonata, Kia Optima and Passat.
Not enough buyers are convinced of that.
I suspect the problem, in addition to the lack of advertising, is that the 2013 Malibu lacks any single, outstanding characteristic that shoppers simply can't ignore. The Fusion has drop-dead looks. The Altima boasts a 38-mpg EPA highway rating. The Accord has a nonpareil reputation and resale value.
What is the Malibu's bragging point?
Chevrolet hopes to recapture the public's attention with a 2014 Malibu, scheduled to reach showrooms this summer. Expect minor changes to the exterior styling, improved interior materials and some tweaks to rear passenger room.
We'll see if Chevy can get the Malibu shipshape again.
Mark Phelan is the Detroit Free Press auto critic. He can be reached at firstname.lastname@example.org.
Show commenting policy
TribLive commenting policy
You are solely responsible for your comments and by using TribLive.com you agree to our Terms of Service.
We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.
While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.
We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers.
We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.
We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.
We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.
We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.
- Wolf reverses Corbett, says deal between Highmark, UPMC doesn’t limit continuity of care to very ill
- Alcoa may close or sell some aluminum plants to cut costs
- Apple to replace AT&T in Dow
- Unemployment rate continues to drop as U.S. adds 295K jobs
- Big banks’ levels of capital strong, Federal Reserve finds
- IPO might test Etsy’s approach to commerce
- Researchers: U.S. lacks proving ground for nuclear energy innovations
- Race toward bigger phones eases
- Worker productivity falls faster than estimated; labor costs rise
- Americans see improved job market but a vulnerable economy, Pew poll finds
- AbbVie to buy leukemia drugmaker Pharmacyclics for $21 billion